NICE rejects Revlimid(Celgene) for Myelodysplastic Syndromes in preliminary appraisal
The National Institute for Health and Care Excellence (NICE) has issued new draft guidance not recommending Revlimid (lenalidomide) from Celgene for the treatment of Myelodysplastic Syndromes (MDS), but has also opened a public consultation on this preliminary decision.This appraisal focuses on the use of Revlimid in the treatment of people with a specific type of MDS that is characterised by a chromosomal abnormality called a deletion 5q cytogenetic abnormality. NICE considered that data provided by Celgene showed uncertainty about whether lenalidomide actually extended patients' lives.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.